Programmed death-ligand 1 (PD-L1) expression in different sarcoma subtypes
Journal of Health Sciences and Medicine · 20.07.2026 · 9 (4) · 977-981
DOI: 10.32322/jhsm.1902291 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Health Sciences and Medicine, online erschienen am 20.07.2026. Verfasst von Gizem Teoman und 3 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
Aims
Sarcomas are rare and heterogeneous mesenchymal malignancies with diverse histological and molecular characteristics. Programmed death-ligand 1 (PD-L1) plays a key role in tumor immune evasion and may serve as a predictive biomarker for immune checkpoint inhibitor therapy. This study aimed to characterize PD-L1 expression across different sarcoma subtypes.
Methods
A total of 54 sarcoma cases diagnosed between January 2020 and September 2025 at the Department of Medical Pathology, Karadeniz Technical University, were retrospectively analyzed. Subtypes included undifferentiated pleomorphic sarcoma (UPS, n=10), liposarcoma (well-differentiated, dedifferentiated, myxoid; n=17), osteosarcoma (n=7), leiomyosarcoma (n=7), myxofibrosarcoma (n=8), and fibromyxoid sarcoma (n=5). PD-L1 expression was assessed immunohistochemically using the validated monoclonal antibody clone 22C3 and quantified by the combined positive score (CPS). PD-L1 positivity was defined as CPS ≥1%.
Results
Overall, 18 of 54 cases (33.3%) exhibited PD-L1 positivity. Expression varied across sarcoma subtypes, with relatively higher positivity rates observed in myxofibrosarcoma (4/8, 50%), leiomyosarcoma (3/7, 42.8%), osteosarcoma (3/7, 42.8%), and UPS (4/10, 25%). Lower PD-L1 expression was observed in fibromyxoid sarcoma (1/5, 20%) and liposarcoma (3/17, 17.6%). Among the liposarcoma subtypes, PD-L1 positivity was detected in one well-differentiated, one dedifferentiated, and one myxoid case.
Conclusion
PD-L1 expression in sarcomas is heterogeneous and subtype-dependent. High-grade pleomorphic tumors, particularly myxofibrosarcomas, leiomyosarcomas, and osteosarcomas, appeared to demonstrate relatively more frequent PD-L1 positivity in this cohort. These findings provide insights into the immunobiology of sarcomas and support the potential rationale for future studies evaluating PD-1/PD-L1-targeted immunotherapies in PD-L1-expressing sarcoma subtypes.
Zitieren
APA
Teoman, G., Karaman, E., Ayas, M. S., & Saygin, I. (2026). Programmed death-ligand 1 (PD-L1) expression in different sarcoma subtypes. Journal of Health Sciences and Medicine, 9(4), 977-981. https://doi.org/10.32322/jhsm.1902291
Vancouver
Teoman G, Karaman E, Ayas MS, Saygin I. Programmed death-ligand 1 (PD-L1) expression in different sarcoma subtypes. Journal of Health Sciences and Medicine. 2026;9(4):977-981. doi:10.32322/jhsm.1902291
BibTeX
@article{Teoman2026,
author = {Teoman, Gizem and Karaman, Elanur and Ayas, Muhammet Salih and Saygin, Ismail},
title = {Programmed death-ligand 1 (PD-L1) expression in different sarcoma subtypes},
journal = {Journal of Health Sciences and Medicine},
year = {2026},
volume = {9},
number = {4},
pages = {977--981},
doi = {10.32322/jhsm.1902291}
}
EUVIMED